Compare · EW vs ICUI
EW vs ICUI
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and ICU Medical Inc. (ICUI): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both companies sit in the Health Care sector. EW focuses on Industrial Specialties, while ICUI focuses on Medical/Dental Instruments.
- EW is the larger of the two at $49.29B, about 12.5x ICUI ($3.94B).
- Over the past year, EW is up 12.5% and ICUI is up 19.4% - ICUI leads by 7.0 points.
- EW has been more active in the news (11 items in the past 4 weeks vs 4 for ICUI).
- EW has more recent analyst coverage (25 ratings vs 15 for ICUI).
- Company
- Edwards Lifesciences Corporation
- ICU Medical Inc.
- Price
- $85.52+1.35%
- $157.77+1.05%
- Market cap
- $49.29B
- $3.94B
- 1M return
- -7.60%
- -13.82%
- 1Y return
- +12.45%
- +19.42%
- Industry
- Industrial Specialties
- Medical/Dental Instruments
- Exchange
- NYSE
- NASDAQ
- IPO
- 1992
- News (4w)
- 11
- 4
- Recent ratings
- 25
- 15
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
ICU Medical Inc.
ICU Medical, Inc., together with its subsidiaries, develops, manufactures, and sells medical devices used in infusion therapy and critical care applications worldwide. The company's infusion therapy products include needlefree connector products under the MicroClave, MicroClave Clear, and NanoClave brands; Neutron catheter patency devices; SwabCap disinfecting caps; Tego hemodialysis connectors; ClearGuard HD, an antimicrobial barrier cap for hemodialysis catheters; and ChemoLock and ChemoClave closed system transfer devices, as well as Diana hazardous drug compounding system for the preparation of hazardous drugs. It also provides IV therapy and diluents, including sodium chloride, dextrose, balanced electrolyte solutions, lactated ringer's, ringer's, mannitol, sodium chloride/dextrose, and sterile water; and irrigation, such as sodium chloride and sterile water irrigation, physiologic solutions, ringer's irrigation, acetic acid irrigation, glycine irrigation, sorbitol-mannitol irrigation, flexible containers, and pour bottle options. In addition, the company offers infusion pumps under the Plum 360 and LifeCare PCA brands; IV mediation safety software, including ICU Medical Mednet, an enterprise medication management platform that connects smart pumps to hospital's electronic health records, asset tracking systems, and alarm notification platforms; and related professional services. Further, it provides critical care products comprising Cogent 2-in-1 and CardioFlo hemodynamic monitoring systems; TDQ and OptiQ cardiac output monitoring catheters; TriOx venous oximetry catheters; Transpac blood pressure transducers; and SafeSet closed blood sampling and conservation systems. The company sells its products to acute care hospitals, wholesalers, ambulatory clinics, and alternate site facilities, such as outpatient clinics, home health care providers, and long-term care facilities. ICU Medical, Inc. was founded in 1984 and is headquartered in San Clemente, California.
Latest EW
- SVP, Corporate Controller Dahl Andrew M. covered exercise/tax liability with 253 shares, decreasing direct ownership by 2% to 14,615 units (SEC Form 4) to satisfy withholding tax
- CVP, JAPAC Markowitz Wayne covered exercise/tax liability with 923 shares, decreasing direct ownership by 5% to 19,371 units (SEC Form 4) to satisfy tax liability
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $54,169 worth of shares (619 units at $87.51) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TMTT, Surgical & IHFM Chopra Daveen covered exercise/tax liability with 398 shares, decreasing direct ownership by 0.90% to 43,926 units (SEC Form 4) to satisfy tax liability
- Edwards Lifesciences Comments on TAVR National Coverage Decision
- Edwards Lifesciences to Present at the Deutsche Bank Healthcare Summit
- SVP, Corporate Controller Dahl Andrew M. sold $49,534 worth of shares (544 units at $91.06), decreasing direct ownership by 4% to 14,868 units (SEC Form 4)
- CVP, EMEACLA Bruls Annette sold $237,907 worth of shares (2,644 units at $89.98), decreasing direct ownership by 13% to 17,984 units (SEC Form 4)
- Edwards Lifesciences Corporation filed SEC Form 8-K: Leadership Update
- CVP, TMTT, Surgical & IHFM Chopra Daveen exercised 31,800 shares at a strike of $72.68 and sold $2,894,440 worth of shares (31,800 units at $91.02) (SEC Form 4)
Latest ICUI
- VP, General Counsel Sanzone Virginia Ruth sold $819,150 worth of shares (4,856 units at $168.69) as part of a pre-agreed trading plan, decreasing direct ownership by 25% to 14,604 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,116,675 worth of shares (6,381 units at $175.00) as part of a pre-agreed trading plan, decreasing direct ownership by 10% to 56,062 units (SEC Form 4)
- Chief Financial Officer Bonnell Brian Michael sold $1,608,143 worth of shares (9,307 units at $172.79) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 62,443 units (SEC Form 4)
- ICU Medical to Participate in Upcoming Investor Conferences
- VP, GM-Infusion Capital Woolson Daniel sold $982,265 worth of shares (5,417 units at $181.33), decreasing direct ownership by 24% to 17,062 units (SEC Form 4)
- Chief Information Officer Sousa Ben sold $401,209 worth of shares (2,250 units at $178.32), decreasing direct ownership by 42% to 3,076 units (SEC Form 4)
- Chief Operating Officer Voigtlander Christian B. sold $1,633,404 worth of shares (8,929 units at $182.93), decreasing direct ownership by 19% to 37,377 units (SEC Form 4)
- Director Finney Elisha W sold $68,978 worth of shares (378 units at $182.48), decreasing direct ownership by 7% to 4,871 units (SEC Form 4)
- SEC Form 10-Q filed by ICU Medical Inc.
- ICU Medical Inc. filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits